E7-0172
TransIT®-BrCa Transfection Reagent – MIR 5506

TransIT®-BrCa Transfection Reagent is the first dedicated breast cancer cell line specific reagent available to researchers. While it delivers efficiently to many breast cancer cell types, it also maintains low cellular toxicity resulting in reduced experimental biases. Broad Spectrum DNA Delivery - Achieve high expression levels in multiple breast cancer cell types. Formulated for Low Cellular Toxicity - Maintain cell density and reduce experimental biases due to toxicity. Superior Transfection Efficiency - TransIT®-BrCa outperforms Lipofectamine™ 2000, in various breast cancer cell lines.